| Name | Title | Contact Details |
|---|
PMV is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey.
Frontier Derm Partners is the premier dermatology clinic serving patients in Washington and Oregon
A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome, diabetes, obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH).
Cansortium Holdings utilizes a unique combination of capital and expertise in making strategic investments to help launch mature and professional cannabis markets. As global regulations evolve, Consortium Holdings is well-positioned to expand its presence in the U.S. and Puerto Rico.
Constab Pharmaceuticals is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.